Last reviewed · How we verify

Heparin Infusion

Columbia University · FDA-approved active Small molecule Quality 5/100

Heparin Infusion is a Small molecule drug developed by Columbia University. It is currently FDA-approved. Also known as: Heparin, new regimen.

At a glance

Generic nameHeparin Infusion
Also known asHeparin, new regimen
SponsorColumbia University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Heparin Infusion

What is Heparin Infusion?

Heparin Infusion is a Small molecule drug developed by Columbia University.

Who makes Heparin Infusion?

Heparin Infusion is developed and marketed by Columbia University (see full Columbia University pipeline at /company/columbia-university).

Is Heparin Infusion also known as anything else?

Heparin Infusion is also known as Heparin, new regimen.

What development phase is Heparin Infusion in?

Heparin Infusion is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing